US2006089304A1PendingUtilityA1

Treatment of psoriasis through down-regulation of the EGF-receptor with topically-applied EGF

Individually held — no corporate assignee on recordPriority: Jun 2, 2000Filed: Oct 3, 2005Published: Apr 27, 2006

Est. expiryJun 2, 2020(expired)· nominal 20-yr term from priority

Inventors:Rudi D. Neirinckx

A61K 31/505A61K 38/1808

PatentIndex Score

Cited by

References

Claims

Abstract

From unrelated but similar fields it is deduced that certain forms of psoriasis can be effectively treated through topical application of EGF-containing formulations. This patent application summarizes the theoretical basis for this finding and requests protection for the idea, while clinical evaluation is in preparation.

Claims

exact text as granted — not AI-modified

1 - 10 . (canceled)  
   
   
       11 . A topical formulation comprising epidermal growth factor (EGF) and a dermatologically acceptable excipient or carrier.  
   
   
       12 . The formulation of  claim 11 , wherein said EGF is in an amount to down regulate the EGF receptor.  
   
   
       13 . The formulation of  claim 11 , wherein said EGF is present at 0.01 to 50 μg/g.  
   
   
       14 . The formulation of  claim 13 , wherein said EGF is present at 0.5-20 μg/g.  
   
   
       15 . The formulation of  claim 11 , further comprising an anti-inflammatory.

Join the waitlist — get patent alerts

Track US2006089304A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.